



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                 |  |                   |                     |
|-----------------|--|-------------------|---------------------|
| Application of: | Palese et al.  | Confirmation No.: | 3723                |
| Serial No.:     | 10/713,732   | Art Unit:         | 1648                |
| Filed:          | November 14, 2003  | Examiner:         | Blumel, Benjamin P. |
| For:            | ATTENUATED NEGATIVE STRAND<br>VIRUSES WITH ALTERED<br>INTERFERON ANTAGONIST<br>ACTIVITY FOR USE AS VACCINES<br>AND PHARMACEUTICALS |                   |                     |
|                 | Attorney Docket No.: 6923-118  |                   |                     |

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop After Final  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent Office of all information coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to documents C35-C40 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of documents C35-C40 are submitted herewith.

- C35: Copy of a letter, dated August 4, 2006, from Andrej Egorov and Sabine Brandt to Peter Palese;
- C36: Copy of a letter, dated August 4, 2006, from Andrej Egorov and Sabine Brandt to Adolfo Garcia-Sastre;

- C37: Copy of a "Communication pursuant to Article 115(2) EPC," dated November 9, 2006, issued in connection with European Patent Application No. 99 927 445.9-1222, with enclosures;
- C38: Copy of a letter, dated November 22, 2006, from Maneula Loidl to Todd Pazdera, with enclosures;
- C39: Copy of a letter, dated April 9, 2007, from Michael F. Fedrick to Laura A. Coruzzi, with enclosures; and
- C40: Copy of an "Expert Opinion," dated October 20, 2006.

Contrary to the allegations in C35-C39, Attorneys for Applicants do not believe that either Dr. Brandt or Dr. Egorov have contributed conceptually to the subject matter of the claims currently pending. The activities alleged in C35-C39 relate to the construction of influenza NS1 mutants reported in references BC, BD and DC of record in the subject application.<sup>1</sup> These have been considered by the Examiner, who has deemed the claims to be free of the prior art.

It is also noted that the publications identified in C40 are of record in the subject application and have been considered by the Examiner.

Identification of C35-C40 is not to be construed as an admission of Applicants or Attorneys for Applicants that these documents are available as "prior art" against the subject application. Attorneys for Applicants respectfully request that the Examiner review the foregoing and that C35-C40 be made of record in the file history of the application.

---

<sup>1</sup> See:

Egorov A *et al.*, "Transfectant Influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells," *J. Virol.* 1998 Aug; 72(8):6437-6441 (reference BC);

Egorov AY *et al.*, "Generation of influenza A transfectant viruses containing deletions of the carboxyl-terminal part of the NS1 protein," in Emergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses. 1997, Dublin, Ireland, Abstract No. 108, p. 104 (reference BD); and

Egorov *et al.*, 1997, "Generation of Influenza A Transfectant Viruses Containing Deletions in the NS1 Protein", Institute of Applied Microbiology," in Emergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses, September 21-26, Dublin, Ireland (reference DC).



Application No. 10/713,732  
Atty. Docket No. 6923-118  
4/11/2008

Pursuant to 37 C.F.R. § 1.97(b)(4), Attorneys for Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should any fee be due, the Patent Office is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: April 11, 2008

*Laura A. Coruzzi*  
Laura A. Coruzzi

30,742  
(Reg. No.)

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

Enclosures